Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor.

[1]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[2]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[3]  A. Garratt,et al.  Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study. , 2002, Seminars in oncology.

[4]  J. Fletcher,et al.  Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. , 2002, Human pathology.

[5]  S. Hirota,et al.  Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. , 2002, Gastroenterology.

[6]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[7]  M. Heinrich,et al.  KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. , 2002, The American journal of pathology.

[8]  W. El-Rifai,et al.  Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. , 2002, Human pathology.

[9]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[10]  Shan Zeng,et al.  The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. , 2002, Blood.

[11]  B. Gunawan,et al.  Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. , 2002, Human pathology.

[12]  A. Ullrich,et al.  Smart drugs: tyrosine kinase inhibitors in cancer therapy. , 2002, Cancer cell.

[13]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[14]  C. Fletcher,et al.  Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. , 2002, American journal of clinical pathology.

[15]  P S Meltzer,et al.  Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. , 2001, Cancer research.

[16]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[17]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[18]  W. Jarnagin,et al.  Results of Hepatic Resection for Sarcoma Metastatic to Liver , 2001, Annals of surgery.

[19]  L. Sobin,et al.  Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Duodenum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 167 Cases , 2001, The American journal of surgical pathology.

[20]  P. D. Dal Cin,et al.  Molecular cytogenetic definition of three distinct chromosome arm 14q deletion intervals in gastrointestinal stromal tumors , 2001, Genes, chromosomes & cancer.

[21]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[22]  J. W. Griffin,et al.  Gastrointestinal Autonomic Nerve Tumor: Immunohistochemical and Molecular Identity With Gastrointestinal Stromal Tumor , 2001, The American journal of surgical pathology.

[23]  C. Capella,et al.  Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa , 2001, Cancer.

[24]  R. Benjamin,et al.  Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Nakajima,et al.  Gastrointestinal stromal tumors and KIT‐positive mesenchymal cells in the omentum , 2001, Pathology international.

[26]  Y. Ma,et al.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.

[27]  M. Debiec‐Rychter,et al.  Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. , 2001, Cancer genetics and cytogenetics.

[28]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[29]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[30]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[31]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[32]  T. Nishida,et al.  Gain‐of‐function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours , 2001, The Journal of pathology.

[33]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[34]  J. Denobile,et al.  CASE REPORT: Adjuvant Radiotherapy for Gastrointestinal Stromal Tumor of the Rectum , 2001, Digestive Diseases and Sciences.

[35]  R. Shlansky-Goldberg,et al.  Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. , 2001, Journal of vascular and interventional radiology : JVIR.

[36]  L. Sobin,et al.  Fine Needle Aspiration of Gastrointestinal Stromal Tumors , 2001, Acta Cytologica.

[37]  S. Hirota,et al.  Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[38]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[39]  L. Sobin,et al.  Gastrointestinal Stromal Tumors and Leiomyosarcomas in the Colon: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases , 2000, The American journal of surgical pathology.

[40]  J. Albores‐Saavedra,et al.  Stromal tumor of the gallbladder with phenotype of interstitial cells of Cajal: a previously unrecognized neoplasm. , 2000, The American journal of surgical pathology.

[41]  L. Sobin,et al.  Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. , 2000, The American journal of pathology.

[42]  L. Sobin,et al.  Immunohistochemical Spectrum of GISTs at Different Sites and Their Differential Diagnosis with a Reference to CD117 (KIT) , 2000, Modern Pathology.

[43]  E. van den Berg,et al.  Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  G. Rosen,et al.  Recurrent gastrointestinal stromal sarcomas. , 2000, Surgical oncology.

[45]  B. Druker,et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.

[46]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[47]  S. Knuutila,et al.  DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. , 2000, Cancer research.

[48]  L. Kindblom,et al.  Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors). , 2000, Cancer genetics and cytogenetics.

[49]  J. Blay,et al.  Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Lasota,et al.  Spindle cell tumor of urinary bladder serosa with phenotypic and genotypic features of gastrointestinal stromal tumor. , 2000, Archives of pathology & laboratory medicine.

[51]  Robert H Lyles,et al.  Extragastrointestinal (Soft Tissue) Stromal Tumors: An Analysis of 48 Cases with Emphasis on Histologic Predictors of Outcome , 2000, Modern Pathology.

[52]  R. Schneider-Stock,et al.  Telomerase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extragastrointestinal sarcomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  S. Knuutila,et al.  High‐resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci , 2000, Genes, chromosomes & cancer.

[54]  P. Flemming,et al.  Hepatic metastases from leiomyosarcoma: A single-center experience with 34 liver resections during a 15-year period. , 2000, Annals of surgery.

[55]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[56]  M. Varella‐Garcia,et al.  Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.

[57]  L. Sobin,et al.  Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. , 2000, The American journal of surgical pathology.

[58]  S. Hirota,et al.  Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. , 2000, The American journal of surgical pathology.

[59]  G. Rosen,et al.  Surgical Resection and Intraperitoneal Chemotherapy for Recurrent Abdominal Sarcomas , 1999, Annals of Surgical Oncology.

[60]  J. Lasota,et al.  Gastrointestinal stromal tumors: recent advances in understanding of their biology. , 1999, Human pathology.

[61]  L. Sobin,et al.  Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. , 1999, The American journal of surgical pathology.

[62]  S. Hirota,et al.  Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. , 1999, Cancer research.

[63]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Goldblum,et al.  Stromal tumors of the abdominal colon: a clinicopathologic study of 20 cases. , 1999, The American journal of surgical pathology.

[65]  S Torihashi,et al.  Blockade of kit signaling induces transdifferentiation of interstitial cells of cajal to a smooth muscle phenotype. , 1999, Gastroenterology.

[66]  C. Moskaluk,et al.  Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.

[67]  L. Regan,et al.  Inhibition of Spontaneous Receptor Phosphorylation by Residues in a Putative α-Helix in the KIT Intracellular Juxtamembrane Region* , 1999, The Journal of Biological Chemistry.

[68]  K. Chorneyko,et al.  Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. , 1999, The American journal of surgical pathology.

[69]  C. Marshall,et al.  Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors , 1999, Oncogene.

[70]  P. Sugarbaker,et al.  Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. , 1999, European journal of cancer.

[71]  L. Kapusta,et al.  Multiple familial gastrointestinal autonomic nerve tumors and small intestinal neuronal dysplasia. , 1999, The American journal of surgical pathology.

[72]  L. Sobin,et al.  KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[73]  M. Fukayama,et al.  Telomerase activity in gastrointestinal stromal tumors , 1998 .

[74]  R. Parwaresch,et al.  Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study. , 1998, Human pathology.

[75]  S. Hirota,et al.  Familial gastrointestinal stromal tumours with germline mutation of the KIT gene , 1998, Nature Genetics.

[76]  A. Kovatich,et al.  CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[77]  S. Torihashi,et al.  Distribution of c-Kit immunopositive cells in normal human colon and in Hirschsprung's disease. , 1998, Journal of pediatric surgery.

[78]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[79]  P. Sugarbaker.  Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. , 1998, Seminars in surgical oncology.

[80]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[81]  J. Goldblum,et al.  Stromal tumors of the jejunum and ileum: a clinicopathologic study of 39 cases. , 1997, The American journal of surgical pathology.

[82]  J. Tworek,et al.  Stromal tumors of the jejunum and ileum. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[83]  S. Suster.  Gastrointestinal stromal tumors. , 1996, Seminars in diagnostic pathology.

[84]  K. Sanders.  A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. , 1996, Gastroenterology.

[85]  S. Knuutila,et al.  DNA copy number losses in chromosome 14: an early change in gastrointestinal stromal tumors. , 1996, Cancer research.

[86]  J M Woodruff,et al.  Subclassification of gastrointestinal stromal tumors based on evaluation by electron microscopy and immunohistochemistry. , 1996, Ultrastructural pathology.

[87]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[88]  L. Ellis,et al.  Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine , 1995, Cancer.

[89]  N. Lydon,et al.  Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[90]  John Malysz,et al.  W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity , 1995, Nature.

[91]  R. Seeger,et al.  Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group , 1994 .

[92]  A. Gown,et al.  CD34 EXPRESSION IN STROMAL TUMORS OF THE GASTROINTESTINAL-TRACT , 1994 .

[93]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[94]  E. Casper,et al.  Gastrointestinal autonomic nerve tumors. A clinicopathological, immunohistochemical, and ultrastructural study of 12 cases. , 1993, The American journal of surgical pathology.

[95]  J. Edmonson,et al.  Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  R. E. Cunningham,et al.  Predicting Prognosis of Gastrointestinal Smooth Muscle Tumors: Role of Clinical and Histologic Evaluation, Flow Cytometry, and Image Cytometry , 1993, The American journal of surgical pathology.

[97]  H. Kitayama,et al.  Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells. , 1993, Leukemia & lymphoma.

[98]  D. Coit,et al.  Lymph Node Metastasis From Soft Tissue Sarcoma in Adults Analysis of Data From a Prospective Database of 1772 Sarcoma Patients , 1993, Annals of surgery.

[99]  R. Pollock,et al.  Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas , 1992, Cancer.

[100]  P. Quirke,et al.  A Flow Cytometric, Clinical, and Histological Study of Stromal Neoplasms of the Gastrointestinal Tract , 1992, The American journal of surgical pathology.

[101]  C. Fletcher,et al.  Gastrointestinal stromal tumours: Correlation of immunophenotype with clinicopathological features , 1991, The Journal of pathology.

[102]  N. Walsh,et al.  Auerbach's myenteric plexus. A possible site of origin for gastrointestinal stromal tumors in von Recklinghausen's neurofibromatosis. , 1990, Archives of pathology & laboratory medicine.

[103]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[104]  L. Cerezo,et al.  Gastrointestinal autonomic nerve tumors. 'Plexosarcomas'. , 1989, Archives of pathology & laboratory medicine.

[105]  R. Turner,et al.  Smooth Muscle Tumors of the Gastrointestinal Tract: Flow Cytometric Quantitation of DNA and Nuclear Antigen Content and Correlation with Histologic Grade , 1988, The American journal of surgical pathology.

[106]  G. Parker,et al.  Gastrointestinal sarcomas. Analysis of prognostic factors. , 1987, Annals of surgery.

[107]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[108]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[109]  W. Grizzle,et al.  Malignant small bowel neoplasm of enteric plexus derivation (plexosarcoma) , 1984, Digestive Diseases and Sciences.

[110]  H. Appelman,et al.  Solitary solid stromal gastrointestinal tumors in von Recklinghausen's disease with minimal smooth muscle differentiation. , 1984, Human pathology.

[111]  M. Mazur,et al.  Gastric stromal tumors Reappraisal of histogenesis , 1983, The American journal of surgical pathology.

[112]  Carney Ja.  The Triad of Gastric Epithelioid Leiomyosarcoma, Pulmonary Chondroma, and Functioning Extra‐Adrenal Paraganglioma: A Five‐Year Review , 1983, Medicine.

[113]  S. Wallace,et al.  Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy , 1980, Cancer.

[114]  O. Beahrs,et al.  Leiomyosarcoma of the small and large bowel , 1978, Cancer.

[115]  H. Appelman,et al.  Cellular leiomyomas of the stomach in 49 patients. , 1977, Archives of pathology & laboratory medicine.

[116]  H. Appelman,et al.  Gastric epithelioid leiomyoma and leiomyosarcoma (leiomyoblastoma) , 1976, Cancer.

[117]  A. Stout.  Bizarre smooth muscle tumors of the stomach , 1962, Cancer.

[118]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[119]  J. Leonard,et al.  Immunotherapy of Non-Hodgkin's lymphomas. , 2001, Hematology. American Society of Hematology. Education Program.

[120]  Y. Shioyama,et al.  Long-term control for a retroperitoneal metastasis of malignant gastrointestinal stromal tumor after chemoradiotherapy and immunotherapy. , 2001, Acta oncologica.

[121]  A. Davis,et al.  Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database , 2001, Annals of Surgical Oncology.

[122]  A. Kuraishi,et al.  Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. , 2001, Gastroenterology.

[123]  J. Griffin,et al.  Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. , 2000, Blood.

[124]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[125]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[126]  Jonathan J. Lewis,et al.  Salvage surgery for patients with recurrent gastrointestinal sarcoma , 2000, Cancer.

[127]  O. S. Nielsen,et al.  Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. , 2000, European journal of cancer.

[128]  L. Sobin,et al.  Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. , 1999, The American journal of surgical pathology.

[129]  J. Lasota,et al.  Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. , 1999, The American journal of pathology.

[130]  S. Steinberg,et al.  Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  S. Knuutila,et al.  DNA copy number changes in gastrointestinal stromal tumors--a distinct genetic entity. , 1998, Annales chirurgiae et gynaecologiae.

[132]  J. Rumessen,et al.  Pacemaker cells in the gastrointestinal tract: interstitial cells of Cajal. , 1996, Scandinavian journal of gastroenterology. Supplement.

[133]  D. Fabbro,et al.  Phenylamino‐Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC) , 1996, Archiv der Pharmazie.

[134]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[135]  Y. Matsuzawa,et al.  Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. , 1996, Blood.

[136]  J. Goldblum,et al.  Stromal tumors of the duodenum. A histologic and immunohistochemical study of 20 cases. , 1995, The American journal of surgical pathology.

[137]  D. Franquemont.  Differentiation and risk assessment of gastrointestinal stromal tumors. , 1995, American journal of clinical pathology.

[138]  E. Atkinson,et al.  Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. , 1992, Annals of surgery.

[139]  C. Cortesini,et al.  Smooth muscle cells, interstitial cells of Cajal and myenteric plexus interrelationships in the human colon. , 1990, Acta anatomica.

[140]  S. Rubin,et al.  Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  G. Farr,et al.  Myosarcomas of the stomach: Natural history, prognostic factors and management , 1982, Cancer.

[142]  E. B. Helwig,et al.  The triad of gastric epithelioid leiomyosarcoma, functioning extra‐adrenal paraganglioma, and pulmonary chondroma , 1979, Cancer.

[143]  H. Appelman,et al.  Sarcomas of the stomach. , 1977, American journal of clinical pathology.

[144]  M. Dockerty,et al.  Leiomyomas and leiomyosarcomas of the small intestine , 1955, Cancer.